Cannabinoid-Pharmaceuticals are Positioned to Take Over the Pharmaceutical Industry and this Company is Paving the Way…

SciSparc Ltd. (NASDAQ: SPRC) has been climbing the ranks of the pharma-industry and is revolutionizing the way the world approaches modern medicine!

With an estimated $16.3 million market cap and a diverse IP portfolio, SPRC is a growth narrative to be paying attention to on the NASDAQ.

The world is on the verge of the cannabinoid-pharmaceutical boom as the study of the application of these molecules has the potential to replace at least part of the opioid market which has had devastating consequences on society economically as well as socially. 

The therapeutic potential of using cannabinoids is limitless and are relatively new and unexplored as many cannabis-based products were relatively unavailable before 2018, making companies like SPRC trail-blazers in a very exciting, up and coming market!

SciSparc Ltd. (NASDAQ: SPRC)’s current candidates are designed to treat Tourette Syndrome, Autism Spectrum Disorder, Epilepsy, Obstructive Sleep Apnea, Alzheimer’s Disease and Agitation, and Pain using cannabinoid- based pharmaceuticals.

More Cannabinoid Highlights:

• The company has a robust IP portfolio all focused on Pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.  This put the company in a multi-billion dollar market: The global cannabis pharmaceuticals market size is expected to reach USD 127.1 billion by 2028! The market is expected to expand at a CAGR of 104.2% from 2022 to 2028.
• While the usage of cannabis has been popular in recent years, it’s only very recently that we are discovering the rare cannabinoid potential. Early studies have shown the exciting efficacy of cannabinoids against a large variety of diseases. For example, preclinical and clinical studies have suggested a potential value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Cannabinoids are inexpensive, as well as natural, which is an exciting contrast to traditional forms of drugs and medicine which often have adverse or addictive consequences.
• Cannabinoids are different and exciting as they interact with many neurotransmitter and neuromodulator systems in the human body, offering the potential to meet currently unmet needs of patients in multiple treatment areas! Some of these areas that SPRC is dedicated to include: pain and inflammation, Tourette syndrome, Alzheimer’s disease, Autism Spectrum Disorder, and Status Epilepticus.

THE STORY

Formerly known as Therapix Biosciences Ltd and headquartered in Tel Aviv, Isreal, SPRC is managed by an established team with a proven track record of execution in drug development, working in concert with a world class, award-winning, scientific advisory board chaired by the renowned Professor Raphael Mechoulam. 

Together they bring decades of experience in pharmaceutical industry, biochemistry and pharmacology, research and development, manufacturing, clinical and regulatory affairs, intellectual property, as well as financial acumen to the SciSparc operation.

The company is a specialty clinical-stage pharmaceutical company that develops drugs based on cannabinoid molecules. Its treatment development programs include SCI-110 for the treatment of Tourette syndrome,  and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. 

SciSparc Ltd. has an agreement with Procaps to develop and commercially manufacture SCI-110, as well as CannAmide, a proprietary formulation of palmitoylethanolamide compound in softgel capsule form. 

The company also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety and  tolerability and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. And agreement with the Sheba Fund for Health Services and Research to perform a pre-clinical study for the evaluation of SCI-210 drug development program for the treatment of status epilepticus; 

PRODUCTS

SCI-110

The company’s proprietary drug candidate, containing both Dronabinol, FDA approved synthetic form of THC, with the endocannabinoid palmitoylethanolamide (PEA).

Designed to stimulate cannabinoid receptors across the Central Nervous System and inhibit the metabolic degradation of endocannabinoids in order to improve uptake of THC, the expected benefits of SCI-110 are an increase in efficiency of oral administration, and in turn a decrease in dosage requirements, tolerability, side effects and adverse events.

This product is being developed under the accelerated regulatory path of 505 (b)(2) application focused on augmenting FDA-approved natural and synthetic cannabinoids to create alternate therapies that potentiate the effects of cannabinoids and target the receptors implicated in modulating the central nervous system.

This approach qualifies us for access to the  FDA’s 505 (b)(2) regulatory strategy, created to facilitate the submission of novel drug candidates that meet specific criteria to the FDA for review. The 505 (b)(2) application provides us with several advantages as compared to a typical New Drug Application, including potential; lower risk and development costs, and a potentially expedited time to market.

Indications currently being investigated for treatment with SCI-110 include:

– Tourette Syndrome- (TS)
– Alzheimer’s Disease and Agitation

SCI-210

SPRC’s proprietary drug candidate containing both cannabidiol (CBD), a non-psychoactive cannabinoid, and with PEA.

This product is initially being developed under the regulation of the Israeli Medical Cannabis Agency (IMCA) – the agency that leads the regularization of the medical cannabis field in Israel and is the first of its kind in the world. It is a complex, unique, innovative and original process. Conducting clinical trials and development under the regulation of the HQR ostensibly enables rapid and specific registration processes in a track that is unique to Israel.

The company intends to further develop the product for markets outside Israel as well. Indications currently being investigated for treatment with SCI-210 include:

• Autism Spectrum Disorder (in  clinical trials)
• Status Epilepticus – a form of seizures that are severe and sometimes fatal. This indication is currently investigated in pre-clinical settings.

SCI-160 

An innovative, proprietary synthetic CB2 receptor agonist created, among others, for the treatment of pain and is currently in preparation towards a phase I clinical study after in successful completion of a serious of  pre-clinical studies. 

The CB2 receptor agonist used in this formulation – HU-433 – was invented and synthesized by Professor Raphael Mechoulam, Ph.D., Chairman of the SciSparc Scientific Advisory Board, and is protected under a patent granted in the U.S. and Europe.

SCI-160 FOR PAIN 

An innovative and proprietary CB2 Receptor (CB2R) agonist formulation intended for the treatment of pain. This specific CB2R agonist was synthesized by Professor Raphael Mechoulam, Ph.D. 

CB2 Receptor specific agonists have been found to be involved in mediating analgesic effects in the peripheral nervous system, without significant detected side effects. CB2R agonist 

After successful completion of pre-clinical studies, the Company will file an FDA Investigational New Drug (IND) Phase I study application.

SCI-160 PRE-CLINICAL RESULTS 

In a Von Frey Test, rats were evaluated for tactile allodynia using a Von Frey Filament. Promising results demonstrate analgesic 40 efficacy is better than morphine. 

CannAmide™ 

A unique palmitoylethanolamide (PEA) oral formulation for the reduction of chronic pain and inflammation. PEA is a cannabinoid mimetic lipid molecule found throughout the body, including the central nervous system. Similar to cannabinoids, PEA has been shown to have neuroprotective, anti-inflammatory, analgesic and anti-convulsant properties.

2021- 2022 CLINICAL & PRE-CLINICAL ACHIEVEMENTS

• SCI–110 for Alzheimer's disease and Agitation - Recruited first patient for the Company’s Phase IIa
• Entered an agreement with two clinical sites: Hannover Medical School in Hannover, Germany, and Tel- Aviv Sourasky Medical Center, in Tel-Aviv, Israel, to further the Company’s Phase IIb clinical study for SCI-110 for patients suffering from Tourette Syndrome
• Entered into agreement with The Sheba Fund for Health Services and Research, to perform a pre- clinical study for the evaluationoftheCompany'sSCI-210drug development program, fort hefor the treatment of Status Epilepticus (SE)
• Received positive top-line results for the Company’s proprietary compound, SCI-160, in a controlled pre-clinical trial on Neuropathic and Post-operative pain.

MARKET POTENTIAL

• The global cannabis pharmaceuticals market size is expected to reach USD 127.1 billion by 2028! The market is expected to expand at a CAGR of 104.2% from 2022 to 2028.
• A report by Market Digits estimates that the psychedelic drug sector could be worth more than $10 billion by 2027, up from $4.75 billion in 2020!

• The global Alzheimer’s therapeutics market is projected to reach $13.68 by 2027 from $7.48 in 2019.

• The global epilepsy market size would grow from $8.8B in 2018 to $9.5B towards the end of 2023 
• The global ASD therapeutics market was approximately $3.3B in 2018 and is expected to reach approximately $4.6B by 2026 
• Tourette Syndrome (TS) market was $80M in 2019 and is expected to reach $98.7M by 2023 
• The global chronic pain treatment market was valued at $77.8B in 2019

THE CANNABIS OPPORTUNITY

The legalization of cannabis in recent years, as well and the rise in awareness among consumers regarding health benefits of cannabis and its growing medical application such as treatment of wide range of diseases and symptoms, including:

Cancer, chronic pain, depression, arthritis, diabetes, glaucoma, migraines, epilepsy, multiple sclerosis, acquired immunodeficiency syndrome (AIDS), amyotrophic lateral sclerosis (ALS), Alzheimer’s, post-traumatic stress disorder (PTSD), Parkinson’s, and Tourette’s have been driving the market for medical cannabis to impressive growth!

This is a multi-billion dollar market! The global cannabis pharmaceuticals market size is expected to reach USD 127.1 billion by 2028! The market is expected to expand at a CAGR of 104.2% from 2022 to 2028.

Furthermore, the global cannabis market size is projected to reach $176 Billion by 2030 with the legalization for medicinal purposes leading this growth.

THE BOTTOM LINE

Tel Aviv-Based, SPRC is a specialty clinical-stage pharmaceutical company with  focus  on creating and enhancing an innovative and proprietary  portfolio of technologies and assets based on cannabinoid pharmaceuticals. 

Cannabinoids have the potential to disrupt the pharmaceutical world and early-studies have shown the exciting efficacy of cannabinoids against a large variety of diseases, putting SPRC in an exciting position as a revolutionary in the profitable, pharmaceutical industry. 

The company is also dipping its toe in the world of psychedelic drugs as they entered a joint venture with Clearmind Medicine Inc. (CSE: CMND), (OTC: CMNDF), (FSE: CWY0) to explore the potential for the creation of innovative compounds in the psychedelic area.

Psychedelics have become an increasingly popular area for medical research and studies. A report by Market Digits estimates that the sector could be worth more than $10 billion by 2027, up from $4.75 billion in 2020!

This plus the company’s robust IP portfolio that uses cannabinoid compounds to treat a multitude of diseases with unmet solutions, shows why the company is slated for impressive growth in 2022!

As we are on a verge of a huge cannabinoid-pharma boom, now is the time to be paying attention to SPRC as it is paving the way in the world of non-traditional medicine!

BEGIN YOUR RESEARCH NOW!

This Website Is Wholly Owned By Tradigital Marketing Group, Inc. (D/B/A “Tradigital Ir”). Our Reports Are Advertorials And Are For General Information Purposes Only.   Never Invest In Any Stock Featured On Our Site Or Emails Unless You Can Afford To Lose Your Entire Investment. The Disclaimer Is To Be Read And Fully Understood Before Using Our Services, Joining Our Email List, As Well As Any Social Networking Platforms We May Use. Please Note Well: Tradigital Ir And Its Employees Are Not  Registered Investment Advisors, Broker-Dealers, Or Member(S) Of Any Association For Other Research Providers In Any Jurisdiction Whatsoever. Release Of Liability: Through Use Of This Website, Viewing Or Using You Agree To Hold Tradigital Ir, Its Operators, Owners, And Employees Harmless And To Completely Release Them From Any And All Liability Due To Any And All Loss (Monetary Or Otherwise), Damage (Monetary Or Otherwise), Or Injury (Monetary Or Otherwise) That You May Incur. The Information Contained Herein Is Based On Sources That We Believe To Be Reliable But Is Not Guaranteed By Us As Being Accurate And Does Not Purport To Be A Complete Statement Or Summary Of The Available Data. Tradigital Ir Encourages Readers And Investors To Supplement The Information In These Reports With Independent Research And Other Professional Advice. All Information On Featured Companies Is Provided By The Companies Profiled Or Is Available From Public Sources And Tradigital Ir Makes No Representations, Warranties, Or Guarantees As To The Accuracy Or Completeness Of The Disclosure By The Profiled Companies. None Of The Materials Or Advertisements Herein Constitute Offers Or Solicitations To Purchase Or Sell Securities Of The Companies Profiled Herein And Any Decision To Invest In Any Such Company Or Other Financial Decisions Should Not Be Made Based Upon The Information Provided Herein. Instead, Tradigital Ir Strongly Urges You To Conduct A Complete And Independent Investigation Of The Respective Companies And Consideration Of All Pertinent Risks. Tradigital Ir’s Full Disclosure Is To Be Read And Fully Understood Before Using Tradigital Ir's Website, Or Joining Tradigital Ir's Email Or Text List. From Time To Time, Tradigital Ir Will Disseminate Information About A Company Via Website, Email, Sms, And Other Points Of Media. By Viewing Tradigital Ir's Website And/Or Reading Tradigital Ir's Email Or Text Newsletter You Are Agreeing ----> Https://Tradigitalir.Com/Disclaimer-Tmg/. All Potential Percentage Gains Discussed In Any Communications Are Based On Calculations From The Low To The High Of The Day. We Are Engaged In The Business Of Marketing And Advertising Companies For Monetary Compensation.  In Compliance With Section 17(B) Of The Securities Act We Are Disclosing That We Have Been Compensated A Fee Pursuant To An Agreement Between Tradigital And Scisparc, Inc. Tradigital Was Hired For A Period Beginning April 2022 And Ending July 2022 To Publicly Disseminate Information About Scisparc, Inc. Via Website, Email, And Sms. We Were Paid Two Hundred Fifty Thousand Usd Via Ach. We Own Fifty Thousand Restricted Common Shares Of Scisparc, Inc., Which Are Eligible For Sale On 10/07/2022. Subsequently, Tradigital Was Hired In July 2022. Pursuant To An Agreement Between Tradigital And Scisparc We Were Paid Thirty Seven Thousand Restricted Common Shares Of Scisparc, Inc., Which Are Eligible For Sale On 01/05/2023. For The Purpose Of This Disclaimer, We Suggest That You Assume We Will Sell All Of Our Shares Once The Restriction Is Lifted On 01/05/2023. Readers Are Advised To Review Sec Periodic Reports: Forms 10-Q, 10k, Form 8-K, Insider Reports, Forms 3, 4, 5 Schedule 13d. Tradigital Ir Is Compliant With The Can-Spam Act Of 2003. Tradigital Ir Does Not Offer Investment Advice Or Analysis, And Tradigital Ir Further Urges You To Consult Your Own Independent Tax, Business, Financial, And Investment Advisors. Investing In Micro-Cap, Small-Cap, And Growth Securities Is Highly Speculative And Carries An Extremely High Degree Of Risk. It Is Possible That An Investor's Investment May Be Lost Or Impaired Due To The Speculative Nature Of The Companies Profiled.The Private Securities Litigation Reform Act Of 1995 Provides Investors A Safe Harbor In Regard To Forward-Looking Statements. Any Statements That Express Or Involve Discussions With Respect To Predictions, Expectations, Beliefs, Plans, Projections, Objectives, Goals, Assumptions Or Future Events, Or Performance Are Not Statements Of Historical Fact May Be Forward-Looking Statements. Forward-Looking Statements Are Based On Expectations, Estimates, And Projections At The Time The Statements Are Made That Involve A Number Of Risks And Uncertainties Which Could Cause Actual Results Or Events To Differ Materially From Those Presently Anticipated. Forward-Looking Statements In This Action May Be Identified Through The Use Of Words Such As Projects, Foresee, Expects, Will, Anticipates, Estimates, Believes, Understands, Or That By Statements Indicating Certain Actions & Quotes; May, Could, Or Might Occur. Understand There Is No Guarantee Past Performance Will Be Indicative Of Future Results In Preparing This Publication, Tradigital Ir Has Relied Upon Information Supplied By Its Clients, As Well As Its Clients’ Publicly Available Information And Press Releases Which It Believes To Be Reliable; However, Such Reliability Can Not Be Guaranteed. Investors Should Not Rely On The Information Contained On This Website. Rather, Investors Should Use The Information Contained In This Website As A Starting Point For Doing Additional Independent Research On The Featured Companies. The Advertisements In This Website Are Believed To Be Reliable, However, Tradigital Ir And Its Owners, Affiliates, Subsidiaries, Officers, Directors, Representatives, And Agents Disclaim Any Liability As To The Completeness Or Accuracy Of The Information Contained In Any Advertisement And For Any Omissions Of Materials Facts From Such Advertisement. Tradigital Ir Is Not Responsible For Any Claims Made By The Companies Advertised Herein, Nor Is Tradigital Ir Responsible For Any Other Promotional Firm, Its Program, Or Its Structure. Tradigital Ir Is Not Affiliated With Any Exchange, Electronic Quotation System, The Securities Exchange Commission, Or Finra. 

THIS WEBSITE IS WHOLLY OWNED BY TRADIGITAL MARKETING GROUP, INC. (D/B/A “TRADIGITAL IR”). OUR REPORTS ARE ADVERTORIALS AND ARE FOR GENERAL INFORMATION PURPOSES ONLY.   NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR EMAIL LIST, AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE. PLEASE NOTE WELL: TRADIGITAL IR AND ITS EMPLOYEES ARE NOT  REGISTERED INVESTMENT ADVISORS, BROKER-DEALERS, OR MEMBER(S) OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE, VIEWING OR USING YOU AGREE TO HOLD TRADIGITAL IR, ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES THAT WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. TRADIGITAL IR ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED OR IS AVAILABLE FROM PUBLIC SOURCES AND TRADIGITAL IR  MAKES NO REPRESENTATIONS, WARRANTIES, OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD, TRADIGITAL IR STRONGLY URGES YOU TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. TRADIGITAL IR’S FULL DISCLOSURE IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING TRADIGITAL IR'S WEBSITE, OR JOINING TRADIGITAL IR'S EMAIL OR TEXT LIST. FROM TIME TO TIME, TRADIGITAL IR WILL DISSEMINATE INFORMATION ABOUT A COMPANY VIA WEBSITE, EMAIL, SMS, AND OTHER POINTS OF MEDIA. BY VIEWING TRADIGITAL IR'S WEBSITE AND/OR READING TRADIGITAL IR'S EMAIL OR TEXT NEWSLETTER YOU ARE AGREEING ----> HTTPS://TRADIGITALIR.COM/DISCLAIMER-TMG/. ALL POTENTIAL PERCENTAGE GAINS DISCUSSED IN ANY COMMUNICATIONS ARE BASED ON CALCULATIONS FROM THE LOW TO THE HIGH OF THE DAY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.  IN COMPLIANCE WITH SECTION 17(B) OF THE SECURITIES ACT WE ARE DISCLOSING THAT WE HAVE BEEN COMPENSATED A FEE PURSUANT TO AN AGREEMENT BETWEEN TRADIGITAL AND PASITHEA THERAPEUTICS CORP. TRADIGITAL  WAS HIRED FOR A PERIOD BEGINNING JANUARY 2022 AND ENDING MARCH 2022 TO PUBLICLY DISSEMINATE INFORMATION ABOUT PASITHEA THERAPEUTICS CORP.  VIA WEBSITE, EMAIL, AND SMS. WE WERE PAID FIVE HUNDRED FORTY-FOUR THOUSAND USD VIA ACH. WE OWN ONE HUNDRED FIFTY THOUSAND RESTRICTED COMMON SHARES OF PASITHEA THERAPEUTICS CORP., WHICH ARE ELIGIBLE FOR SALE ON 03/18/2022. FOR THE PURPOSE OF THIS DISCLAIMER, WE SUGGEST THAT YOU ASSUME WE WILL SELL ALL OF OUR SHARES ONCE THE RESTRICTION IS LIFTED ON 03/18/2022. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D. TRADIGITAL IR IS COMPLIANT WITH THE CAN-SPAM ACT OF 2003. TRADIGITAL IR DOES NOT OFFER INVESTMENT ADVICE OR ANALYSIS, AND TRADIGITAL IR FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP, SMALL-CAP, AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS, OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH THE USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTES; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS IN PREPARING THIS PUBLICATION, TRADIGITAL IR HAS RELIED UPON INFORMATION SUPPLIED BY ITS CLIENTS, AS WELL AS ITS CLIENTS’ PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CAN NOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED ON THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, TRADIGITAL IR AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES, AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. TRADIGITAL IR IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS TRADIGITAL IR RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM, OR ITS STRUCTURE. TRADIGITAL IR IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION, OR FINRA.